| Literature DB >> 27035164 |
Arman Jahangiri1, Aaron T Chin1, Patrick M Flanigan1, Rebecca Chen1, Krystof Bankiewicz1, Manish K Aghi1.
Abstract
Glioblastoma is the most common malignant brain tumor, and it carries an extremely poor prognosis. Attempts to develop targeted therapies have been hindered because the blood-brain barrier prevents many drugs from reaching tumors cells. Furthermore, systemic toxicity of drugs often limits their therapeutic potential. A number of alternative methods of delivery have been developed, one of which is convection-enhanced delivery (CED), the focus of this review. The authors describe CED as a therapeutic measure and review preclinical studies and the most prominent clinical trials of CED in the treatment of glioblastoma. The utilization of this technique for the delivery of a variety of agents is covered, and its shortcomings and challenges are discussed in detail.Entities:
Keywords: BBB = blood-brain barrier; CED = convection-enhanced delivery; GDL = gadoteridol-loaded liposomes; HSV-TK = herpes simplex virus–thymidine kinase; IL-4 = interleukin-4; OS = overall survival; PFS = progression-free survival; TF = transferrin; TMZ = temozolomide; TRAIL = tumor necrosis factor–related apoptosis-inducing ligand; blood-brain barrier; convection enhanced delivery; glioblastoma; oncology
Mesh：
Year: 2016 PMID： 27035164 PMCID： PMC5571827 DOI： 10.3171/2016.1.JNS151591
Source DB: PubMed Journal: J Neurosurg ISSN： 0022-3085 Impact factor: 5.115